Michael E. Wechsler, MD, a pulmonologist at National Jewish Health, discusses the challenges associated with differentiating similar eosinophilic conditions, including eosinophilic asthma, from one another.
Michael E. Wechsler, MD, a pulmonologist at National Jewish Health, discusses the challenges associated with differentiating similar eosinophilic conditions, including eosinophilic asthma, from one another.
Transcript
What are some of the challenges with distinguishing eosinophilic asthma from other diagnoses associated with abnormal eosinophil activity?
Well, you have to recognize that eosinophils are involved, and you can do that easily by evaluating the number of eosinophils in the blood. And so, with any disease state, you want to look for eosinophils at or in the tissue. And there aren't major challenges in terms of distinguishing from other eosinophilic conditions, other than the fact that there can be some overlap between the different conditions.
So for instance, there's eosinophilic asthma, that's basically just airway disease with eosinophils in the blood and/or the airway. Then, there's an entity called chronic eosinophilic pneumonia, which is basically eosinophilic asthma with some chronic sinus disease and pulmonary infiltrates. And then there is an entity called EGPA, or eosinophilic granulomatosis with polyangiitis. And that's an entity that's characterized by asthma, eosinophilia, sinus disease, pulmonary infiltrates, and then vasculitis in 1 or more end organ, including in neuropathy. And lastly, there are hypereosinophilic syndromes, which aren't really associated with asthma but have eosinophilia and organ involvement in systemic manifestations.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More